Lindsay Bealor Greenleaf

ADVI’s head of market access policy strategy discusses how the Trump administration’s efforts.

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Drug pricing restrictions are likely to impact drug launches, especially for medications expected to be sought after by Medicare patients.

While they may be linked, the administration’s DTC drug coupon site is not necessarily the entirety of its MFN efforts.